A. Siva Rama Prasad

Managing Director

The market for the pellets industry is experiencing robust growth and is projected to expand significantly in the coming years. The pellets industry is experiencing noteworthy trends that are reshaping its landscape and the growing demand for complex generic molecules has steered pharmaceutical companies towards specialized pellets. Technological advancements in automated manufacturing processes and innovative coating techniques are further propelling the industry forward, optimizing production efficiency and product quality. These trends indicate a strong market demand for pellets and underscore the industry's potential for growth and development. However, along with opportunities, the industry also faces challenges.

Consumers often encounter issues related to product quality due to variations in manufacturing processes and timely delivery issues may arise from supply chain disruptions. Ensuring stringent quality control measures is vital to address these concerns and provide reliable products to consumers. To address these concerns, Credo Life, a leading pharmaceutical company, emerges as a reliable solution provider. With its customer-centric approach and expertise in complex generic molecules, taste masking, and controlled-release formulations, Credo Life stands out as a trusted partner in delivering high-quality pellets to meet the diverse needs of the pharmaceutical industry.

K. Madhava Rao, Director

Credo Life is a pharmaceutical company headquartered in Hyderabad, Telangana, India. With its inception in July 2014 and full-fledged operations beginning in December 2017, Credo has established itself as a specialist in manufacturing specialized pellets and granules. Its diverse product portfolio includes IR pellets, SR pellets, Controlled release pellets, taste mask granules, DC granules, multivitamins, and immunosuppressant, positioning the firm as a prominent player in the market. As a company driven by innovation and a commitment to excellence, the firm primarily focuses on larger and more complex generic products rather than conventional generics. One of its major growth catalysts has been its antifungal product, which has propelled the firm's success in recent years. Furthermore, the company has experienced rapid expansion in the CNS segment. Its unique value proposition lies in its customer-centric approach, functioning as a Contract Development and Manufacturing Organization (CDMO). This allows Credo to work closely with its clients, developing bespoke products tailored to their specific needs, and differentiating Credo Life from competitors who offer standardized products.

Strengthening Product Quality Assurance

Quality, on-time delivery, consistency, and comprehensive documentation are critical aspects of this industry, and Credo takes pride in successfully addressing these pain points. Its cutting-edge facility, considered one of the finest in India, gives the firm a competitive edge. Every aspect of its manufacturing process is optimized, utilizing a state-of-the-art human interface system for automatic and precise operations. When selecting vendors, the company prioritizes product quality and stability over cost sensitivity, ensuring high standards across the supply chain. As a B2B enterprise, Credo supplies its pharmaceutical products to end manufacturers throughout India and in ROW markets. Its recent certification with EU-GMP standards, along with scheduled audits by reputable bodies such as GCC, Russian, and Korean authorities, underscores its unwavering commitment to maintaining superior quality and compliance.“Credo life is continuously exploring new and innovative ways to grow. We are working on complex molecules to accelerate credos future growth”, says K. MadhavaRao, Director Marketing.

A. Vamsi Krishna, Director

Its Research and Development (R&D) department plays a pivotal role in driving its growth. With a dedicated team of approximately 25 skilled professionals, Credo invests heavily in R&D to expand its capabilities further. "Over the last five years, we have achieved an impressive turnover of 100 crores and garnered numerous regulatory approvals. Looking ahead, we are poised for substantial growth, with a vision to double or even triple our current output within three to five years, says A. Vamsi Krishna, Director at Credo Life.

Expanding Global Footprint

Expanding its market presence in Europe, the firm has set its sights on every other global market. Presently, Credo operates in India, Bangladesh, Vietnam, Russia, Sri Lanka, Iraq, Nepal, Algeria, Turkey, and the Philippines, having secured regulatory approvals from various countries, including Europe, Vietnam, Iran, and Sri Lanka. Recently, it acquired EU-GMP certification from Europe, further validating its commitment to global excellence. The company's dynamic workforce of 250 professionals empowers Credo Life for future growth, with plans to double the team size as it expands its capacities. The firm's management team, boasting a collective experience of nearly 75 years, ensures efficient decision-making and successful operations.

Credo Life holds steadfast to its core values, centered on quality, consistent delivery, and meticulous documentation. As it endeavors to become an impact player in the pharmaceutical industry, Credo remains dedicated to developing customer-centric products that are difficult to replicate or imitate. Its robust R&D setup, bolstered by a strong management and manufacturing services team, positions it to excel in this competitive sector. Moreover, the company is continuously exploring new opportunities to develop complex products, striving to deliver groundbreaking innovations in the coming years.“Credo believes in providing good quality products, on time delivery and progressing together”, mentions A. Siva Rama Prasad, Managing Director.

In conclusion, Credo Life stands poised to leverage its strengths, expand its global presence, and maintain its unwavering commitment to excellence in the specialized pellets and granules market. "With a relentless focus on customer satisfaction, product quality, and innovation, we look forward to continuing our successful journey as a trailblazing pharmaceutical enterprise" concludes, A Vamsi Krishna.